<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nyxoah — News on 6ix</title>
<link>https://6ix.com/company/nyxoah</link>
<description>Latest news and press releases for Nyxoah on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 19 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nyxoah" rel="self" type="application/rss+xml" />
<item>
<title>Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First</description>
</item>
<item>
<title>Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-to-participate-in-the-oppenheimer-36th-annual-healthcare-medtech-and-services-conference</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-to-participate-in-the-oppenheimer-36th-annual-healthcare-medtech-and-services-conference</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgium – March 11, 2026, 10:05 pm CET /</description>
</item>
<item>
<title>Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-to-release-fourth-quarter-and-full-year-2025-financial-results-on-march-19-2026-77</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-to-release-fourth-quarter-and-full-year-2025-financial-results-on-march-19-2026-77</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET –</description>
</item>
<item>
<title>Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-announces-the-signature-of-a-memorandum-of-understanding-with-sheikh-shakhbout-medical-city-hospital-to-improve-osa-therapy-management-and-accelerate-access-to-genio-in-the-middle-east</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-announces-the-signature-of-a-memorandum-of-understanding-with-sheikh-shakhbout-medical-city-hospital-to-improve-osa-therapy-management-and-accelerate-access-to-genio-in-the-middle-east</guid>
<pubDate>Wed, 18 Feb 2026 21:05:00 GMT</pubDate>
<description>Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East Mont-Saint-Guibert, Belgium – February 18, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced conti</description>
</item>
<item>
<title>Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-invests-further-expanding-belgian-210500621</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-invests-further-expanding-belgian-210500621</guid>
<pubDate>Wed, 21 Jan 2026 21:05:00 GMT</pubDate>
<description>Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Mont-Saint-Guibert, Belgium – January 21, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced an important investment in Belgium to further scale its manufacturing capacity to support its c</description>
</item>
<item>
<title>Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-announces-preliminary-results-fourth-210500991</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-announces-preliminary-results-fourth-210500991</guid>
<pubDate>Mon, 12 Jan 2026 21:05:00 GMT</pubDate>
<description>INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 Strong Start in First Full Quarter of U.S. Commercialization Mont-Saint-Guibert, Belgium – January 12, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA)</description>
</item>
<item>
<title>Publication relating to transparency notification</title>
<link>https://6ix.com/company/nyxoah/news/publication-relating-transparency-notification-060000943</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/publication-relating-transparency-notification-060000943</guid>
<pubDate>Mon, 12 Jan 2026 06:00:00 GMT</pubDate>
<description>REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), January 12, 2026, 7:00 am CET / 1:00 am ET – In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BNP Paribas Asset Management On January 8, 2026, Nyxoah received a transparency notification from BNP Paribas Asset Management SA. Based o</description>
</item>
<item>
<title>Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-present-44th-annual-j-210500009</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-present-44th-annual-j-210500009</guid>
<pubDate>Mon, 29 Dec 2025 21:05:00 GMT</pubDate>
<description>Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference Mont-Saint-Guibert, Belgium – December 29, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, Jan. 15</description>
</item>
<item>
<title>Nyxoah Announces Issuance of First Tranche of Convertible Bonds</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-announces-issuance-first-tranche-210500655</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-announces-issuance-first-tranche-210500655</guid>
<pubDate>Fri, 19 Dec 2025 21:05:00 GMT</pubDate>
<description>Nyxoah Announces Issuance of First Tranche of Convertible Bonds Mont-Saint-Guibert, Belgium – December 19, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the issuance of the first tranche of the convertible bond financing entered into with an entity managed by</description>
</item>
<item>
<title>Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-announces-commercial-launch-genio-060500879</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-announces-commercial-launch-genio-060500879</guid>
<pubDate>Wed, 17 Dec 2025 06:05:00 GMT</pubDate>
<description>Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the NetherlandsFirst Genio implants successfully performed at OLVG West and Zuyderland hospitals Mont-Saint-Guibert, Belgium – December 17, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio</description>
</item>
<item>
<title>Publication relating to transparency notifications</title>
<link>https://6ix.com/company/nyxoah/news/publication-relating-transparency-notifications-213000314</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/publication-relating-transparency-notifications-213000314</guid>
<pubDate>Tue, 02 Dec 2025 21:30:00 GMT</pubDate>
<description>REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 2, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below. Robert Taub / BMI Estate On November 27, 2025, Nyxoah received a transparency notification from Robert Taub and related person BMI Est</description>
</item>
<item>
<title>Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-participate-piper-sandler-37th-210500246</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-participate-piper-sandler-37th-210500246</guid>
<pubDate>Thu, 27 Nov 2025 21:05:00 GMT</pubDate>
<description>Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – 27 November, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thu</description>
</item>
<item>
<title>Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-genio-therapy-receives-significant-064500891</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-genio-therapy-receives-significant-064500891</guid>
<pubDate>Wed, 26 Nov 2025 06:45:00 GMT</pubDate>
<description>Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive news for Nyxoah’s U.S. commercial rollout by strengthening hospital and ASC economics Mont-Saint-Guibert, Belgium – November 26, 2025, 7:45 am CET / 1:45 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA)</description>
</item>
<item>
<title>Information on the total number of voting rights and shares</title>
<link>https://6ix.com/company/nyxoah/news/information-total-number-voting-rights-213000897</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/information-total-number-voting-rights-213000897</guid>
<pubDate>Thu, 20 Nov 2025 21:30:00 GMT</pubDate>
<description>REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 20, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6.504.688,76 Total number of securities carrying voting rights: 43,026,460 (all ordinary shares) Total number o</description>
</item>
<item>
<title>Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-secures-financing-commitments-u-003000595</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-secures-financing-commitments-u-003000595</guid>
<pubDate>Fri, 14 Nov 2025 00:30:00 GMT</pubDate>
<description>INSIDE INFORMATIONREGULATED INFORMATION Correction and ReplacementNyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond. This press release replaces the press release issued on November 13, 2025, at 10:11 pm CET / 4:11 pm ET in order to replace and correct the gross proceeds of the private placement and regi</description>
</item>
<item>
<title>Nyxoah Reports Third Quarter 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-reports-third-quarter-2025-211200529</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-reports-third-quarter-2025-211200529</guid>
<pubDate>Thu, 13 Nov 2025 21:12:00 GMT</pubDate>
<description>REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. Mont-Saint-Guibert, Belgium – November 13, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulati</description>
</item>
<item>
<title>Nyxoah to Participate in the Stifel 2025 Healthcare Conference</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-participate-stifel-2025-healthcare-210500822</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-participate-stifel-2025-healthcare-210500822</guid>
<pubDate>Mon, 03 Nov 2025 21:05:00 GMT</pubDate>
<description>Nyxoah to Participate in the Stifel 2025 Healthcare Conference Mont-Saint-Guibert, Belgium – November 3, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Stifel 2025 Healthcare Conference on Tuesday, Nov. 11, 2025. The Company is scheduled to present at 9:20am Eastern Time the same day via webcast. A live w</description>
</item>
<item>
<title>Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-release-third-quarter-2025-211000022</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-release-third-quarter-2025-211000022</guid>
<pubDate>Thu, 30 Oct 2025 21:10:00 GMT</pubDate>
<description>Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025 Mont-Saint-Guibert, Belgium – Thursday, October 30, 2025, 10:10pm CET / 5:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Thursday, November 13, 2025. Company management will host a c</description>
</item>
<item>
<title>Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-announces-first-u-commercial-050000189</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-announces-first-u-commercial-050000189</guid>
<pubDate>Mon, 06 Oct 2025 05:00:00 GMT</pubDate>
<description>Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System Early Commercial Launch Demonstrates Strong Physician Demand, Successful Pre-Authorizations, and Widespread Payor Coverage Mont-Saint-Guibert, Belgium – October 6, 2025 7:00 CET / 1:00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the first U.S. commercial patients have been successfu</description>
</item>
<item>
<title>Nyxoah Provides an Update on Expanded Middle East Presence</title>
<link>https://6ix.com/company/nyxoah/news/nyxoah-provides-expanded-middle-east-201000949</link>
<guid isPermaLink="true">https://6ix.com/company/nyxoah/news/nyxoah-provides-expanded-middle-east-201000949</guid>
<pubDate>Tue, 23 Sep 2025 20:10:00 GMT</pubDate>
<description>Nyxoah Provides an Update on Expanded Middle East Presence New Centers in Dubai, Kuwait, and Abu Dhabi Following First Genio® Implant in the Region Earlier in 2025 Mont-Saint-Guibert, Belgium – September 23, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced the continued expansion of its commercial footprint in the Middle East, following the</description>
</item>
</channel>
</rss>